V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210027978 | 210038741 | 1.82 | 84.2 | Curative (C) | 2016-07-13 | 2016-07-27 | Dasatinib | N | N | 210041618 | DASATINIB |
| 210027979 | 210013592 | 1.56 | 60.7 | Palliative (P) | 2019-02-15 | 2019-07-25 | CYCLOPHOSPHAMIDE | N | N | 210041621 | CYCLOPHOSPHAMIDE |
| 210027980 | 210013595 | 1.71 | 0 | null | 2018-03-04 | 2018-03-31 | UKALL XII Maintenance (3 months) | 02 | N | 210041626 | INOTUZUMAB OZOGAMICIN |
| 210027981 | 210022495 | 1.74 | null | Curative (C) | 2014-04-19 | 2014-09-23 | Cyclophosphamide+Fludara+TBI Allo | N | N | 210041630 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 210027982 | 210013600 | 1.83 | 102.3 | Curative (C) | 2016-06-16 | 2016-07-18 | Procarbazine | null | N | 210041637 | PROCARBAZINE |
| 210027983 | 210033677 | 0 | 75.3 | Curative (C) | 2017-07-18 | 2018-03-15 | Dasatinib | N | N | 210041643 | DASATINIB |
| 210027984 | 210022498 | 1.63 | 27.4 | Curative (C) | 2017-02-15 | 2017-02-15 | Vinblastine weekly | 2 | N | 210041654 | VINBLASTINE |
| 210027985 | 210013604 | 1.88 | 106.75 | Not known (9) | 2017-03-17 | 2017-03-17 | Dasatinib | 2 | N | 210041679 | DASATINIB |
| 210027986 | 210022500 | null | 72.8 | Palliative (P) | 2019-07-23 | 2019-07-24 | R GCVP | 02 | N | 210041680 | BEVACIZUMAB |
| 210027987 | 210013608 | null | 101 | Palliative (P) | 2018-07-05 | 2018-08-29 | Cyclophosphamide oral | N | N | 210041701 | CYCLOPHOSPHAMIDE |
| 210027988 | 210013609 | 1.6 | null | Curative (C) | 2013-11-06 | 2013-11-16 | IDELALISIB | 02 | N | 210041709 | CHLORAMBUCIL + OFATUMUMAB |
| 210027989 | 210013611 | 1.75 | 0 | Palliative (P) | 2017-05-21 | 2018-01-16 | IDELALISIB | N | N | 210041726 | BENDAMUSTINE |
| 210027990 | 210035154 | null | 99.7 | Curative (C) | 2014-06-24 | 2014-11-25 | Vinblastine weekly | Y | N | 210041774 | VINBLASTINE |
| 210027991 | 210013613 | 1.82 | 87.5 | Adjuvant (A) | null | 2014-01-07 | Brentuximab | 2 | null | 210041789 | CLOFARABINE + CYTARABINE |
| 210027992 | 210013615 | 1.71 | 64.4 | Disease modification (D) | 2014-06-20 | 2014-06-20 | Fludarabine IV | 02 | N | 210041797 | BEVACIZUMAB + IRINOTECAN |
| 210027993 | 210036193 | 1.67 | 87.4 | Adjuvant (A) | 2016-02-07 | 2016-08-01 | Cytarabine intrathecal | N | null | 210041807 | CARBO + ETOPOSIDE + VINCRISTINE |
| 210027994 | 210013616 | null | null | Neo-adjuvant (N) | 2017-05-22 | 2017-06-02 | Bortezomib (weekly) | 02 | N | 210041810 | DOXORUBICIN |
| 210027995 | 210013620 | 1.66 | 21.3 | Palliative (P) | 2019-04-14 | 2019-04-14 | DAUNORUBICIN + VINCRISTINE | 02 | N | 210041817 | CISPLATIN + VINORELBINE |
| 210027996 | 210013624 | 1.65 | 79.75 | Disease modification (D) | 2016-01-05 | 2016-10-03 | Bevacizumab + LOMUSTINE | 2 | null | 210041820 | CVP |
| 210027997 | 210013627 | 1.57 | 78 | Adjuvant (A) | 2015-10-10 | 2015-10-16 | CYCLOPHOSPHAMIDE + ETOPOSIDE + Procarbazine | N | N | 210041854 | R CODOX-M/ R IVAC |
| 210027998 | 210028117 | 1.7 | 66.8 | Curative (C) | 2015-11-24 | 2015-11-30 | Cytarabine low (10to20mg/m2) IV/SC | 02 | N | 210041861 | OFATUMUMAB |
| 210027999 | 210013633 | 1.76 | null | Adjuvant (A) | 2014-04-18 | 2014-08-15 | BR14 TRIAL | 2 | N | 210041863 | IRINOTECAN + TEMOZOLOMIDE |
| 210028000 | 210013635 | 1.64 | 65.3 | Curative (C) | 2014-12-22 | 2014-12-22 | Alemtuzumab + Cyclophos TBI Allo | N | Y | 210041872 | GEMCARBO |
| 210028001 | 210028119 | 1.63 | 64 | Curative (C) | 2016-04-06 | 2016-04-06 | Brentuximab Vedotin | 99 | N | 210041872 | BEVACIZUMAB + IRINOTECAN |
| 210028002 | 210028119 | 1.83 | 84.2 | Disease modification (D) | 2018-05-09 | 2018-05-09 | Docetaxel 75mg/m2 (21 day) | N | N | 210041872 | CYTARABINE HD + METHOTREXATE HD |
| 210028003 | 210013639 | null | 72.3 | Curative (C) | 2015-12-18 | 2016-03-08 | CARBOPLATIN + VINORELBINE | N | N | 210041935 | CISPLATIN + VINORELBINE + RT |
| 210028004 | 210013640 | 1.61 | 63.1 | Curative (C) | 2015-06-04 | 2015-07-12 | FCR IV - Cycle 2 onwards | Y | null | 210041947 | CVP |
| 210028005 | 210013641 | 1.79 | 63.05 | Adjuvant (A) | 2018-10-06 | 2018-12-08 | Bortezomib + Cyclophos + Dex | 2 | N | 210041947 | BEVACIZUMAB + TEMOZOLOMIDE |
| 210028006 | 210022519 | 0 | 82.2 | Neo-adjuvant (N) | 2018-08-21 | 2018-10-07 | Cytarabine low (10to20mg/m2) IV/SC | Y | N | 210041971 | DHAP - R |
| 210028007 | 210035157 | 1.73 | null | Curative (C) | 2017-12-29 | 2017-12-29 | CYCLOPHOSPHAMIDE + ETOPOSIDE + NELARABINE | N | null | 210041981 | ICE |
| 210028008 | 210013643 | 1.75 | null | Curative (C) | null | 2018-01-30 | CYCLOPHOSPHAMIDE + ETOPOSIDE + Procarbazine | N | N | 210041983 | FEC |
| 210028009 | 210022521 | null | 75 | Adjuvant (A) | null | 2015-09-29 | IDARUBICIN + MERCAPTOPURINE + METHOTREXATE + VINCRISTINE | N | N | 210042007 | ABVD |
| 210028010 | 210013646 | 0 | 57.2 | Curative (C) | 2016-12-03 | 2017-01-14 | PENTOSTATIN + RITUXIMAB | N | N | 210042028 | CAPECITABINE + CISPLATIN + RT |
| 210028011 | 210013648 | null | 12.7 | Curative (C) | 2015-03-29 | 2015-04-04 | Cytarabine High Dose | N | null | 210042033 | TAMIGA TRIAL |
| 210028012 | 210022524 | null | null | Curative (C) | 2018-10-06 | 2018-10-07 | MERCAPTOPURINE + METHOTREXATE + VINCRISTINE | Y | null | 210042039 | BEVACIZUMAB + TEMOZOLOMIDE + RT |
| 210028013 | 210022524 | 1.76 | null | Curative (C) | 2017-02-17 | 2017-08-04 | TRASTUZUMAB | N | N | 210042039 | CISPLATIN + LOMUSTINE + VINCRISTINE |
| 210028014 | 210013651 | null | null | Curative (C) | 2015-09-04 | 2015-11-26 | ICE (no GCSF) | Y | N | 210042045 | PEMBROLIZUMAB |
| 210028015 | 210022525 | 1.8 | 76.45 | Curative (C) | 2014-04-08 | 2014-04-14 | ALL UKALL2003 C: Ph VII Maintenance | 01 | N | 210042045 | POMALIDOMIDE |
| 210028016 | 210022527 | null | 18.1 | Curative (C) | 2017-01-18 | 2017-01-18 | CARBOPLATIN + LOMUSTINE + VINCRISTINE | N | null | 210042056 | PACKER INDUCTION VINCRISTINE + RT |
| 210028017 | 210013654 | 1.68 | 135 | Palliative (P) | 2015-01-26 | 2015-02-05 | Lenalidomide 15mg (Cycle 1 to 25) | N | null | 210042059 | UKALL 60+ TRIAL |
| 210028018 | 210013656 | 1.89 | null | Curative (C) | 2015-12-22 | 2016-02-05 | TAMIGA trial | N | null | 210042061 | CODOX M |
| 210028019 | 210028131 | null | 50 | Curative (C) | 2015-02-20 | 2015-03-03 | CYCLET | N | N | 210042066 | BEVACIZUMAB + LOMUSTINE |
| 210028020 | 210028132 | null | 61.9 | Curative (C) | 2016-08-04 | 2016-08-05 | CLOFARABINE + CYCLOPHOSPHAMIDE + ETOPOSIDE | N | N | 210042069 | CISPLATIN + CYCLOPHOSPHAMIDE + ETOPOSIDE |
| 210028021 | 210013661 | 1.68 | 64 | Curative (C) | 2017-07-09 | 2017-07-09 | FLUOROURACIL + IRINOTECAN | 02 | N | 210042072 | DABRAFENIB + TRAMETINIB |
| 210028022 | 210013662 | 1.74 | 33.2 | Curative (C) | 2014-10-21 | 2014-10-26 | Bevacizumab + LOMUSTINE | Y | N | 210042107 | EURO-EWING |
| 210028023 | 210013662 | 1.73 | null | null | 2018-02-27 | 2018-03-02 | IPILIMUMAB + NIVOLUMAB | null | N | 210042107 | IRINOTECAN + TEMOZOLOMIDE |
| 210028024 | 210013663 | 1.83 | 88.7 | Curative (C) | 2016-07-30 | 2016-08-02 | Fludarabine + Melphalan RIC Allo | N | N | 210042133 | SUNITINIB |
| 210028025 | 210013663 | 1.75 | null | Curative (C) | 2014-02-16 | 2014-02-16 | R CODOX M | N | N | 210042133 | IRINOTECAN + TEMOZOLOMIDE |
| 210028026 | 210013665 | null | 69.3 | Curative (C) | 2017-11-26 | 2017-12-27 | Cyclophosphamide High Dose | 02 | null | 210042147 | ICE |
| 210028027 | 210013670 | 1.77 | 70.2 | Curative (C) | null | 2016-09-28 | DA 3 + 10 | N | N | 210042153 | GEMCARBO |